Compare NINE & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NINE | GDTC |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5M | 24.8M |
| IPO Year | 2018 | 2023 |
| Metric | NINE | GDTC |
|---|---|---|
| Price | $0.33 | $1.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 39.0K |
| Earning Date | 10-30-2025 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $571,171,000.00 | $573,193.00 |
| Revenue This Year | $4.56 | $5.37 |
| Revenue Next Year | $1.41 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.59 | ★ 63.03 |
| 52 Week Low | $0.29 | $1.50 |
| 52 Week High | $1.78 | $4.05 |
| Indicator | NINE | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 36.83 |
| Support Level | $0.29 | $1.53 |
| Resistance Level | $0.51 | $1.66 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 19.37 | 10.48 |
Nine Energy Service Inc is a North American onshore completion and production services provider. It targets unconventional oil and gas resource development. It operates in one segment, Completion Solutions. The Completion Solutions segment offers cementing services; completion tools, including liner hangers and accessories, frac sleeves, fully composite frac plugs, and specialty open hole float equipment and centralizers and other services. It operates in the U.S, Canada, and other countries where majority of the revenue is generated from the United States.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.